Introduction
Eosinophilic gastrointestinal disorders (EGIDs) are chronic inflammatory conditions characterized by dense eosinophilic inflammation of the gastrointestinal tract. They are classified according to the affected region of the gastrointestinal tract and include eosinophilic esophagitis (EoE), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EoC). The etiologic mechanisms remain to be clarified, but recent evidence points towards foodbased antigens as a central trigger in activating the inflammatory cascades that underlie the disease pathology. Of these entities, EoE is best characterized, with eosinophilic infiltration of the esophagus being its distinguishing feature [1] . EGE is a rare disease occurring in both children and adults [2] . It is characterized by eosinophilic infiltration of the stomach or intestinal wall, leading to a variety of gastrointestinal symptoms [2] . EoC is considered to be a non-IgE-mediated allergic response to food proteins and usually affects children, although a few adult cases have also been reported. The main feature of this rare disease is extensive eosinophilic infiltration of the colon [3] . This article provides an overview of the epidemiology, diagnosis, treatment, and management of these disorders from the Japanese and Swiss perspectives.
Epidemiology
In general, EoE has been reported more frequently in Western countries than in Asia [4] . Four recent epidemiological studies focusing on the incidence of EoE have been conducted in Japan, which included patients undergoing endoscopy either due to upper gastrointestinal symptoms or as part of an annual medical check-up [5] [6] [7] [8] . Altogether, the results from these studies indicate that the incidence of EoE ranges from 0.01 to 0.13%. In contrast, another Japanese study reported a much higher incidence (2.5%) [9] . Unlike the patients from the previous studies, this study included patients who complained of chest or epigastric symptoms suggestive of EoE, including heartburn, dysphagia, epigastric pain, chest pain, acid regurgitation, food impaction, and vomiting [9] . Epidemiological studies on EoE performed in Europe and North America indicate that the incidence is on the rise. Two regional population-based studies in Switzerland revealed that the incidence and cumulative prevalence of EoE has increased rapidly over the past 10-20 years, with a current prevalence of 24-43 per 100,000 inhabitants (0.024-0.043%) [10, 11] . Similarly, a Spanish study estimated a prevalence of 1 in 2,250 (0.04%) [12] . The findings from studies using national databases in Europe and the USA suggest that the rising incidence has not yet reached a plateau [13] [14] [15] . There also appears to be a seasonal trend in the volume of disease diagnoses, and in many patients, EoE is a chronic relapsing disease [14] .
Although EoE is increasingly prevalent, there are very little data on the prevalence and incidence of the other EGIDs. In the USA, the prevalence of EGE is estimated at 22-28 per 100,000 persons [16] . A US study estimated the prevalence of EGE and EoC at 8.4/100,000 and 3.3/100,000, respectively, with a predominance in females for these non-EoE conditions [17] . Given the strong immunological component in the disease pathology, it is not surprising that concomitant atopic diseases were observed in many patients, particularly in children [17] . There are very little epidemiological data on the prevalence and incidence of EGE in Asian countries [18] , but there are likely to be differences in gastrointestinal symptoms between Asians and Caucasians [4] . These may be due to differences in the prevalence of infectious agents (such as Helicobacter pylori ) as well as differences in dietary habits [4] .
Patient Characteristics
The majority of EoE patients are men in their 20s or 30s, although data from other studies have indicated later presentations [18] [19] [20] [21] . A retrospective Australian study, which confirmed a diagnosis of EoE in 31 adults (24 men and 7 women), indicated that the mean age at diagnosis was 34 years [19] , in contrast to a mean age at diagnosis of 49 years in a Japanese study [18] . In the Australian patients, symptoms (predominantly dysphagia) had been present for an average of 4.5 years prior to diagnosis [19] . The male predominance may be related to variations in a gene located on the X-chromosome which have been associated with EoE. It is not surprising that among children, EoE is also more frequently observed in boys [22, 23] .
EoE is strongly associated with certain allergic conditions, including food allergies, environmental allergies, asthma, and atopic dermatitis. An estimated 26-86% of adults and 42-93% of children diagnosed with EoE also have another allergic condition [14, 22, [24] [25] [26] [27] [28] [29] [30] [31] . Related allergic disorders include asthma, allergic rhinitis, urticaria, hay fever, atopic dermatitis, food allergy, or drug allergies [29, 31] . A study in children with EoE indicated that 68% had a positive skin or radioallergosorbent test against a median of 7 food allergens [28] . A recent metaanalysis concluded that there is no clear link between EoE and celiac disease [32] . EoE was found with a high prevalence in patients with inherited connective tissue disorders [33] . Antibiotic use in infancy was associated with higher odds of having EoE [34] . In addition, cesarean delivery, preterm birth, and formula-only or mixed (infant formula and breast milk) feeding also showed trends toward increased odds for developing EoE [34] .
As its name implies, EGE can affect the entire gastrointestinal tract, from the stomach to the colon [35] [36] [37] [38] . The clinical features of EGE are related to the location, extent, and layer(s) of bowel with eosinophilic infiltration [39] . Although studies have suggested that EGE has a predilection for the distal antrum and proximal small bowel, this may reflect sampling bias because of the greater accessibility of these areas for biopsy [39] . EGE can affect patients of any age, but it most frequently presents in the third through the fifth decade with a peak age of onset in the third decade [38] . Similar to EoE, a large proportion of patients with EGE (around 50%) have a history of allergic diseases including asthma, defined food sensitivities, eczema, or rhinitis [38, 40, 41] . Interestingly, a recent Japanese study revealed that the prevalence of infection by H. pylori was significantly lower in patients with EGE and EoE compared to control subjects, implying a role of Th1/ Th2 imbalance in the etiology of these disorders [42] .
Genetics
Under normal conditions, the esophagus is devoid of eosinophils. Interestingly, the normal distribution of eosinophils in the gastrointestinal tract has only recently been thoroughly evaluated, including the definition of normal values in the different gastrointestinal segments. An increasing number of eosinophils from the stomach to the right-sided colon are observed with a decreasing number of eosinophils in the left-sided colon [43] . Eosinophils synthesize and secrete numerous important inflammatory and regulatory molecules including cytokines, chemokines, and growth factors that function in the regulation of the intestinal microenvironment [43] . Although the exact mechanisms through which eosinophils are involved in the pathogenesis of the EGIDs remain unknown, recent evidence suggests the dysregulation of specific cytokines in EoE and EGE [44] . Elevated plasma concentrations of IL-5 and IL-15 were observed in Japanese EoE and EGE patients compared to normal controls, a finding which correlated with blood eosinophil count [44] . A recent transcriptome analysis comparing the EoE gene signatures between Japanese and US patients identified several common IL-13-inducible and eosinophil-related genes, including eotaxin-3/CCL26, suggesting that the molecular pathogenic mechanisms of EoE may be similar in Asian and Western countries [45] . Genome-wide association studies have identified several loci associated with EoE, namely TSLP/WDR36, c11orf30, and STAT6 (also associated with atopic and autoimmune diseases), as well as ANKRD27 and CAPN14 [46, 47] . The latter two loci are thought to be specific to EoE [47] . The current hypothesis for EoE suggests an interplay between allergic sensitization alongside an IL-13-inducible esophageal response that may involve CAPN14 [46] . Further studies are urgently needed in order to understand the molecular mechanisms involved and to identify new therapeutic targets.
Diagnosis
International guidelines for the diagnosis and management of EoE exist, but not yet for EGE and EoC. In Japan, a research group of the Ministry of Health, Labor and Welfare has recently announced recommendations for the diagnosis and management of EoE and EGE. In Switzerland, clinicians rely on the guidelines established by the American College of Gastroenterology (ACG) [48] and a recent consensus statement [49] for EoE. The diagnostic principles for EoE are based on the concept that this appears to be a chronic, immune-mediated disease defined clinically by symptoms related to esophageal dysfunction and histologically by eosinophil-driven inflammation [49] . The diagnostic criteria for EoE are summarized in table 1 . A diagnosis of EoE is based on findings of esophageal dysfunction, a dense eosinophilic infiltrate ( ≥ 15 eosinophils/high-power field) that persists under an at least 8-week treatment with proton pump inhibitors (using a standard or double dose), and exclusion of differential diagnoses that can also be associated with esophageal eosinophilia ( table 2 ) [48] . In Japan, besides the clinical and histological pillars, endoscopic findings are frequently used to support an EoE diagnosis. Longitudinal furrows are the most frequently reported abnormality, observed in 52% of the patients, followed by white plaques and concentric rings [5-9, 18, 21, 50] . A recent Japanese study reported that longitudinal furrows corresponded to the highest positive and negative predictive values [9] . In Swit- zerland, imaging (scans and endoscopic ultrasound) or functional exams (pH-metric studies and manometry) are not routinely used for diagnosis as these are unspecific. Of note, the ACG guidelines do not recommend systematic imaging by a thoracic scan or by endoscopic ultrasound for establishing an EoE diagnosis [48] . In both Asia and Europe, blood analyses are routinely performed. A workup by an allergist is recommended for every EoE patient (specific IgE, atopy patch testing, and skin prick testing).
Worldwide, similar criteria are used in the diagnosis of EGE and EoC. Peripheral blood eosinophilia and findings obtained from computed tomography or ultrasound are frequently used, since these tests are noninvasive and easily performed in clinical settings [18] . The presence of eosinophilic infiltration of the gastrointestinal tract upon biopsy and/or the presence of eosinophilic ascitic fluid, lack of involvement of other organs, and the absence of other known causes of intestinal eosinophilia are important criteria for establishing a diagnosis ( table 3 ). An overview of the differential diagnoses for EGE is given in table 4 . Endoscopic findings of mucosal disease are nonspecific and often include nodular or polypoid gastric mucosa, erythema, or erosions. Because the stomach and duodenum are the most commonly affected sites, endoscopic evaluation is typically limited to the upper gastrointestinal tract, although colonoscopy is recommended for patients with significant diarrhea. A key diagnostic criterion for mucosal EGE is the presence of a higher number of eosinophils than expected upon microscopic examination of gastrointestinal biopsies [51] [52] [53] . As there are no formally defined histological cutoff values for the number of eosinophils per high-power field for EGE, the diagnosis should be confirmed by an experienced pathologist to assess if the number of eosinophils is higher than expected for a particular area.
Treatment and Management
A combination of dietary, pharmacological, and endoscopic interventions (esophageal dilation) are used for the treatment of EoE [54] . The use of pharmacological agents and dietary changes target the inflammation associated with EoE, whereas esophageal dilation addresses should be taken from both the stomach and small intestine with additional biopsies of areas with visual abnormalities -In patients with mucosal disease, upper endoscopy with biopsy of the stomach and small intestine is diagnostic in at least 80% of patients; however, it is important to note that mucosal biopsies are normal in patients with muscular or subserosal disease -Full-thickness biopsy: as negative endoscopic mucosal biopsies do not definitively rule out muscular or subserosal EGE, laparoscopic full-thickness biopsy is necessary to establish the diagnosis; in patients with bowel wall thickening and/or obstruction, this also serves to exclude an underlying malignancy 1 Guideline by the Japanese Ministry of Health, Labor and Welfare. No other eosinophil thresholds are available. Table 2 . Differential diagnoses: other diseases that should be differentiated from EoE [52] EoE differential diagnoses -Celiac disease -Esophageal Crohn's disease -Gastroesophageal reflux disease -Proton pump inhibitor-responsive esophageal eosinophilia -Achalasia -Esophageal infection (e.g. herpes and candida) -Drug hypersensitivity -Connective tissue disorders (e.g. scleroderma and dermatomyositis) -Hypereosinophilic syndrome tissue remodeling and fibrotic complications in the esophagus. In both Asian and Western countries, the use of corticosteroids (topical and less frequently systemic) forms the cornerstone of treatment for EoE. The topical glucocorticoids budesonide and fluticasone are currently the first-line therapies of choice. In a cohort of adolescent and adult Swiss patients, treatment with oral budesonide was able to achieve a high degree of clinical and histological remission (80 and 90%, respectively) [55] . An adverse effect that emerged from this study was an increased risk of oroesophageal candidiasis [55] . Data from the Swiss EoE cohort indicated that swallowed topical corticosteroid therapy with either budesonide or fluticasone reduced the risk of food bolus impactions [56] . Although systemic corticosteroids (i.e. prednisone or methylprednisolone) have been shown to rapidly resolve the symptoms of EoE, several problems have emerged in connection with their use. First, symptoms reappear after tapering off the steroid dose [57] . Second, there is concern over the adverse effects of long-term systemic corticosteroid use. Therefore, systemic treatments are reserved for patients with severe disease or who are refractory to topical agents. Through their anti-inflammatory effects, the use of proton pump inhibitors has been shown to ameliorate eosinophilia in the esophagus, yielding clinical and histological remission in up to 50% of EoE patients [58, 59] . In this case, the term 'proton-pump inhibitor-responsive esophageal eosinophilia' should be used.
Since food allergies are commonly reported in patients with EoE, an important therapeutic approach involves the identification and elimination of dietary antigens [57] . Milk products and wheat are the most commonly identified drivers of eosinophilic inflammation in the esophagus. Dietary therapy in EoE involves the use of elemental diets (amino acid-based formulas) and elimination diets. Elemental diets appear to be effective at achieving disease remission, but the poor taste and the need to forego all foods are a major barrier to long-term adherence. Elimination diets based on the avoidance of specific food allergens are effective in some patients, but the success of this strategy hinges on the predictive value of allergy testing in identifying the offending antigens [60] . In Switzerland, milk products and wheat products represent staple foods; thus, few patients are willing to adopt elimination diets but prefer long-term treatment with swallowed topical corticosteroids. Another treatment that is used in Switzerland is esophageal dilation. This is a safe and effective strategy that can provide long-lasting relief from EoE symptoms [61] . It should be noted that dilation has no effect on the underlying inflammation, and despite the high degree of patient acceptance, some experience postprocedural pain [61] . Esophageal dilation is associated with a low risk for esophageal perforation. Finally, patients may also participate in ongoing clinical trials, including those evaluating targeted therapies such as monoclonal antibodies against IL-13, IL-5, or IL-15.
For EGE, the treatment modalities are similar in Japan and Switzerland. Due to the rarity of this disease, there is a lack of randomized controlled trials to guide the choice of therapy. The use of local (i.e. budesonide) or systemic (i.e. prednisone) corticosteroids forms the mainstay of treatment. Unlike in EoE, the use of topical corticosteroids may not achieve symptom relief in the majority of EGE patients, since the affected areas lie deeper within the gastrointestinal tract. One of the problems is that the dosage and formulation of topical corticosteroids have yet to be defined for the use in EGE [62] . A case in point is the controlled ileal-release capsule formulation of budesonide, which delivers the drug to the ileum but is less effective for drug delivery to the stomach or duodenum [62] . The use of systemic corticosteroids is associated with adverse effects such as weight gain, steroid-induced diabetes, arterial hypertension, acne, and effects on the adrenal axis. Immunomodulatory agents (i.e. azathioprine) are often used for patients with steroid-refractory disease or for the management of recurrent disease flares. Azathioprine, however, is not without unwanted effects (i.e. drug-induced hepatitis, pancreatitis, and leukopenia). As for EoE, elimination diets have also been used with some success. The treatment modalities for EGE reflect a compromise between drug-related adverse effects and relief of disease symptoms. Due to the rarity of the EGIDs, many unanswered questions remain with respect to disease pathogenesis, classification, diagnosis, and treatment. Since 2009, the International Eosinophilic Esophagitis Activity Index (EEsAI) study group has been developing and validating instruments to assess the activity of EoE at the level of symptoms, quality of life, endoscopy, and histology. The development and validation of tools which can integrate patient-reported outcomes, quality of life, and endoscopic and histological activity in adult and pediatric EoE patients will be useful for clinical management. Since November 2015, EoE patients from several cantons of Switzerland have been systematically included into the prospective Swiss EoE Cohort Study (SEECS). The creation of patient registries and the inclusion of patients in ongoing clinical trials will provide much-needed information on disease incidence, prevalence, natural history, and real-life efficacy of new treatments.
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